Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Beckman Laser Institute University of California Irvine
Information provided by (Responsible Party):
Montana Compton, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00842283
First received: February 11, 2009
Last updated: May 19, 2014
Last verified: May 2014
  Purpose

The researcher want to study compounds present in the skin, which may increase blood vessel formation. This is important because if certain compounds are increased in these skin lesions which help promote blood vessel formation and growth of skin lesions, these compounds may be the targets of future treatments. Future medications may be able to directly target these compounds in order to slow blood vessel formation and treat certain skin conditions.


Condition Intervention Phase
Dermatologic Diseases
Other: dermatologic diseases
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • expression of various angiogenic factors in dermatologic diseases. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: November 2008
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
dermatologic diseases
dermatologic diseases
Other: dermatologic diseases
dermatologic diseases
Other Name: dermatologic diseases

Detailed Description:

Subjects who agree to participate will have one or more of their skin lesions biopsied. Such biopsies would be done the same way they would be done in clinic by your regular dermatologist. Additionally, normal skin biopsied as well so the researcher can compare normal skin to the skin lesion.

The biopsy specimen will be processed by doctors in the UC Irvine Dermatopathology Department and prepare the biopsy specimen for testing. The researcher want to do specific tests on the biopsy in order to study the compounds in the skin lesion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years of age or older.
  • willing to have a skin biopsy

Exclusion Criteria:

  • under 18 years of age
  • unable to carry out instructions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00842283

Locations
United States, California
Beckman Laser Institute Medical clinic
Irvine, California, United States, 92612
Sponsors and Collaborators
Montana Compton
Beckman Laser Institute University of California Irvine
Investigators
Principal Investigator: Kristen Kelly, MD Beckman Laser Institute University of California Irvine
  More Information

No publications provided

Responsible Party: Montana Compton, Administrative Nurse Research Coordinator Beckman Laser Institute, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00842283     History of Changes
Other Study ID Numbers: LAMMP-RR 01192
Study First Received: February 11, 2009
Last Updated: May 19, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Irvine:
dermatologic diseases

Additional relevant MeSH terms:
Skin Diseases

ClinicalTrials.gov processed this record on July 28, 2014